Shattuck Labs, Inc. Stock Price, News & Analysis

Shattuck Labs, Inc. (NASDAQ: STTK) has announced participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. The company specializes in developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Its lead program, SL-172154, is currently in multiple Phase 1 trials, targeting CD47 immune checkpoints while activating the CD40 pathway. Additionally, Shattuck is advancing its GADLEN™ platform, designed to connect gamma delta T cells with tumor antigens. The company is focused on transparent investor communication and compliance with regulatory obligations.

Shattuck Labs, Inc. (NASDAQ: STTK) provided a corporate update on January 9, 2023, emphasizing its focus on clinical execution for 2023. Key achievements in 2022 included the advancement of SL-172154 through various clinical trials for platinum-resistant ovarian cancer and its combination therapies. The company plans several critical data readouts in 2023, including results for SL-172154 in acute myeloid leukemia and higher-risk myelodysplastic syndromes. Shattuck ended Q3 2022 with approximately $185.1 million in cash, which is projected to sustain operations into the second half of 2024.

Shattuck Labs (NASDAQ: STTK) reported its Q3 2022 financial results and significant clinical advancements. The company completed enrollment in a Phase 1 trial for SL-172154 in platinum-resistant ovarian cancer, with complete data expected mid-2023. Additionally, the first patient was dosed in a combination trial with liposomal doxorubicin. Despite a cash position of $185.1 million, Shattuck incurred a net loss of $24.6 million for the quarter, increasing from $17.4 million YoY. The company anticipates its cash will fund operations into H2 2024.

Shattuck Labs, Inc. (NASDAQ: STTK) announced preclinical proof-of-concept data for its GADLEN platform at the 2022 SITC Annual Meeting. The data revealed two GADLEN candidates targeting CD20 and B7-H3, which enhanced the ability of γδT cells to kill tumor cells. These bispecific engagers showed a selective cytotoxic effect against B7-H3 expressing tumors and CD20 expressing lymphoma cells, indicating potential applications in treating various cancers. The platform's modularity allows for targeting specific tumor antigens, which could advance cancer therapies significantly.

Shattuck Labs (NASDAQ: STTK) announced its participation in three investor conferences in November and December 2022. CEO Dr. Taylor Schreiber will present at the Cowen’s 6th Annual IO Next Summit on November 11 and the Evercore ISI HealthCONx Conference on November 29. CFO Andrew Neill will present at the Piper Sandler Healthcare Conference on December 1. The company focuses on developing bi-functional fusion proteins to treat cancer and autoimmune diseases through its proprietary ARC® platform, which targets immune checkpoints and pathways simultaneously.

Shattuck Labs (NASDAQ: STTK) will report its Q3 2022 financial results on November 8, 2022, at 4:30 p.m. ET, during a conference call led by CEO Taylor Schreiber. Experts anticipate insights into the company's innovative bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Currently, the SL-172154 and SL-279252 programs are in Phase 1 trials, utilizing Shattuck's proprietary ARC® platform. Investors can listen to the live webcast on Shattuck's website.

Shattuck Labs (NASDAQ: STTK) announced it will present a poster on its innovative bispecific Gamma Delta T Cell Engager (GADLEN) platform at the Society for Immunotherapy of Cancer's 37th Annual Meeting from November 8-12, 2022, in Boston. The presentation, titled "Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity," will feature insights from Dr. Suresh de Silva and Dr. Derek Franklin. Shattuck is focused on developing novel biologic therapies for cancer and autoimmune diseases, leveraging its proprietary ARC® platform.

Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2022. The first event is Citi's 17th Annual BioPharma Conference on September 8, where CEO Taylor Schreiber will present at 2:40 p.m. ET. The second event is H.C. Wainwright's 24th Annual Global Investment Conference on September 12 at 7:00 a.m. ET. Both presentations will be available via live webcast on the company's website, with replays accessible for up to 90 days.

Shattuck Labs reported its Q2 2022 financial results, noting a net loss of $27.4 million, increasing from $23.6 million in Q2 2021. Cash and equivalents totaled $214.2 million, down from $268.8 million at the end of 2021. The company is advancing its SL-172154 clinical trials, with enrollment expected for a Phase 1B trial in ovarian cancer in Q3 2022, and initial data from these and other trials anticipated in 1H 2023. Shattuck maintains guidance that current cash resources will sustain operations into H2 2024 while progressing on its clinical programs.